Open

Phase 2 Study of ALXN2050 in Generalized Myasthenia Gravis

EValuating the effectiveness of ALXN2050, an oral molecule that has the potential to provide a unique option to patients with gMG who suffer from debilitating and often incapacitating symptoms

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

Demograophics, history pertaining to MG diagnosis and treatments. Other relevant medical history. Muscle testing assessment will be done at every cliinic visit; along with Study blood sample and ECG at some visits

Incentives

reimbursement for travel and time.

In-person visits:
20

Phone or online visits:
6

Total length of participation:
125 weeks

Looking for Specific Volunteers

Able to participate:

Myasthenia Gravis

Not eligible if:

Pregnant or lactating
any other confounding medical condition.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

James Howard
Neurology

Study Type

Clinical or Medical
Interventional

Study Topics

Brain, Head, Nervous System

IRB Number

22-0110

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.